HEK293T cells were obtained from the American Type Culture Collection. Human bone marrow Written informed consent for the use of material for scientific studies was obtained from these patients according to institutional guidelines. Mononuclear cells were isolated by Ficoll-Hypaque density sedimentation and MM cells were purified using the EasySep TM Human CD138 Positive Selection Kit (Stem Cell Technologies).
Lentiviral transduction
MELK specific shRNA cloned into the pLKO.1 vector was obtained from Sigma-Aldrich (#TRCN0000196420). Lentiviral particles were produced using a lipofectamine 3000 (ThermoFisher Scientific) based protocol. Briefly, HEK293T cells were transfected with pLKO.1 vector in conjunction with pMD2.G envelope plasmid (kind gift from Didier Trono, Addgene plasmid #12259) and pCMVR8.74 packaging plasmid (kind gift from Didier Trono, Addgene plasmid #22036). Viral supernatant was collected 24h and 52h post transfection. For lentiviral transduction, HMCLs (5x 10 5 ) were spin transfected (1h, 800g) with 1 ml of viral supernatant and incubated overnight. Transduced MM cells were selected with puromycin (1µg/ml) and used for further experiments. Cells transduced with pLKO.1 carrying scrambled shRNA (kind gift from David Sabatini, Addgene plasmid #1864) served as control.
Flow cytometry
Induction of apoptosis was analysed by AnnexinV/7-AAD staining (BD Biosciences) 72h post treatment. Cell cycle analysis was performed 48h post treatment using FxCycle™ PI/RNase Staining solution (ThermoFisher Scientific). Depolarization of the mitochondrial membrane potential was analysed 24h post treatment using JC-1 assay (ThermoFisher Scientific). Cells positive for cleaved-PARP were determined 20h post treatment using anti-cleavedPARP antibody (BD Biosciences) and the Cytofix/Cytoperm staining procedure (BD Biosciences). All assays were performed according to the manufacturer's instructions. Analyses were performed on a FACScan and FACS Canto II (BD Biosciences).
Quantitative RT-PCR
Total RNA was isolated using RNeasy kit (Qiagen), and cDNA synthesis was performed with M-MuLV reverse transcriptase (New England Biolabs). AURKA, IRF4, MYC, CCND1, CCNB1, PLK1, EZH2, FOXM1, DEPDC1 and MCL-1 expression levels were analysed by quantitative PCR (qPCR) using TaqMan Universal PCR Master Mix and pre-designed TaqMan gene expression assays (ThermoFisher Scientific). RPLPO served as endogenous control. Reactions were carried out in 25 μl volumes and run on the ABI Prism7300 platform (ThermoFisher Scientific).
Western Blot
Protein lysates were obtained using complete lysis solution (Sigma-Aldrich), quantified with Coomassie Protein-Assay Reagent (ThermoFisher Scientific) and analysed by immunoblotting using anti-MELK, anti-PLK1, anti-EZH2, anti-GAPDH, anti-βactin, anti-MCL1, anti-IRF4, anti-cleaved caspase3 (all from CellSignalingTechnology), anti-DEPDC1 (Abcam) and anti-FOXM1 antibodies (SantaCruz Biotechnology). After incubation with HRP-conjugated secondary antibodies immunoblots were analysed using ECL Prime Western Blotting Detection Reagent (GE Healthcare LifeSciences) and
the FusionSolo 6S imaging-system (Vilber-Lamour).
In vivo study
For studies in the murine 5TGM.1 myeloma model, 5x10 5 5TGM.1GFP+ cells were injected i.v. in C57/KaLwRij mice (Envigo). When mice presented signs of myeloma, such as paraplegia, all mice were sacrificed, blood was collected through an intracardiac puncture and spleen, femur and tibia were isolated. Bone marrow infiltration of MM cells was determined by flow cytometry. Blood cell counts were performed using Cell-Dyn 3700 (Abbott). Serum paraprotein levels were determined with the mouse IgG2b ELISA read-set-go kit (eBioscience) according to the supplier's protocol. A paraplegia score was determined throughout the study as required by our ethics protocol. This score takes the activity, posture and occurrence of hind-limb paraplegia into account.
Analysis of GEP data
The following datasets from the Gene Expression Omnibus (GEO) were selected for this study: GSE24080 (551 newly-diagnosed MM patients), GSE6477 (15 healthy controls, 22 MGUS patients, 24 SMM patients, 73 newly-diagnosed and 28 relapsed MM patients), GSE31161 (346 TT2-baseline and 127 TT2-relapse samples, 433 TT3-baseline and 29 TT3-relapse samples), GSE2113 (7 MGUS patients, 39 MM patients and 6 patients suffering from plasma cell leukemia (PCL)), GSE13591 (5 healthy controls, 11 MGUS, 133 MM, and 9 PCL patients) and GSE9782 (264 relapsed and/or refractory MM patients treated with bortezomib or dexamethasone). Raw CEL files were downloaded from GEO and analyses were performed on gcrma-normalized samples in R using the 'affy' package from Bioconductor. For GSE9782, mas5 expression sets were retrieved for analysis using the GEOquery package, since raw CEL files are not provided for this study.
Categorization of newly-diagnosed patients into distinct GEP-defined subgroups (GSE24080) was performed by Zhan et al. (Blood, 2006) . This study identified seven distinct GEP-subgroups of myeloma. Four of these subgroups represent major genetic lesions in MM that arise from translocations on the immunoglobulin heavy chain locus. These groups are identified by the spiked expression of the translocated genes on the partner chromosome (CCND1, CCND3, c-MAF or MAFB, and MMSET). In contrast, hyperdiploidy had a distinct gene expression profile (associated with hyperdiploid karyotypes). The low bone disease group distinguished itself by low level expression of Wnt signalling inhibitory genes (DKK1 and FRZB), interferon-induced genes and high expression of endothelin 1 (EDN1). Clinically, these patients were characterized by a lower number of MRI-defined focal lesions. The proliferation (PR) subgroup is defined by overexpression of various cell cycle/proliferation associated genes and cancer testis antigens as well as higher GEP-defined proliferation index. Finally, the authors defined a myeloid signature which is characterized by contamination of MM cell samples with myeloid and/or normal plasma cells but also superior clinical performance.
Metacore enrichment analysis
Pathway enrichment analysis was performed using MetaCore TM (version 6.28) analytical software.
Genes differentially expressed (min 2-fold up-or downregulation in samples with high MELK expression versus samples with low MELK expression, adjusted P-value <0.05) were imported into MetaCore. Enrichment analyses (hypergeometric test) were run on 3 ontologies: Pathway maps, GO processes, and process networks. These ontologies were ordered according to their P-value, based on hypergeometric distribution. 10 0,45 5 0.5 0,36 5 0.5 0,25 5 100 0,24 5 1.0 0,26 5 1.0 0,21 5 250 0,29 5 2.5 0,33 5 2.5 0,21 10 10 0,49 10 0.5 0,46 10 0.5 0,34 10 100 0,21 10 1.0 0,36 10 1.0 0,29 10 250 0,23 10 2.5 0, 35 BMSC PBMC #1 PBMC #2 PBMC #3
